25-Hydroxy vitamin D deficiency predicts inferior prognosis in Hodgkin lymphoma

Jia-Qi Qin,Hua Yin,Jia-Zhu Wu,Rui-Ze Chen,Yi Xia,Li Wang,Hua-Yuan Zhu,Lei Fan,Jian-Yong Li,Jin-Hua Liang,Wei Xu
DOI: https://doi.org/10.1016/j.leukres.2021.106580
IF: 3.715
2021-06-01
Leukemia Research
Abstract:<p>The study investigated serum 25-Hydroxy vitamin D (25-(OH)D) deficiency and its prognostic values of patients newly diagnosed Hodgkin lymphoma (HL). With seventy-seven patients enrolled, the median level of 25-(OH)D was 44.5 nmol/L (range, 15.5‒100.9 nmol/L) and 16 (20.8%) of them were considered as 25-(OH)D deficiency. With a median follow-up of 28 months (range, 4‒56 months), the 2-year progression-free survival (PFS) and overall survival (OS) rate were 75.3%±5.5% and 94.7%±3.0%, respectively. Patients with deficient 25-(OH)D level had inferior PFS (<em>P&lt;</em>0.001) as well as OS (<em>P&lt;</em>0.001). In multivariate Cox analysis, 25-(OH)D deficiency was observed as an independent prognostic factor for both PFS (hazard ratio (HR) 3.323, 95% CI 1.527–7.229, <em>P</em> = 0.002) and OS (HR 5.819, 95% CI 1.322−25.622, <em>P</em> = 0.020). Receiver-operator characteristic (ROC) curve showed International Prognostic Score (IPS) plus 25-(OH)D deficiency (IPS-D) predicted more accurately than IPS in PFS (AUC: 0.735 (95% CI 0.622−0.829) vs. 0.701 (95% CI 0.586−0.800), <em>P</em> = 0.033) and OS (AUC: 0.864 (95% CI 0.767−0.932) vs. 0.825 (95% CI 0.722−0.902), <em>P</em> = 0.028). All these findings suggest that serum 25-(OH)D level may be an adjunctive indicator to predict prognosis in HL patient.</p>
oncology,hematology
What problem does this paper attempt to address?